Sanofi has announced an increase in net income from continuing operations for the fourth quarter (Q4) of 2024, reaching €880m ($916m) compared to a loss of €119m ($123.9m) in the same period in 2023.
The company’s income before tax and associates and joint ventures also increased to €1.06bn compared to a €75m loss in Q4 2023.
Go deeper with GlobalData
The operating income for the quarter was reported at €1.18bn against €384m in the same quarter of the previous year.
Gross profit for the quarter stood at €7.84bn, up on €7.43bn in the same period of 2023.
Sanofi’s net sales for Q4 2024 also saw a rise, reaching €10.56bn against €9.68bn in the same quarter of 2023.
The company’s research and development expenses amounted to €2.25bn in Q4 2024.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataIn 2025, Sanofi anticipates sales growth by a mid-to-high single-digit percentage at constant exchange rates.
The company has outlined plans to execute a share buyback programme of €5bn during the year, preferably through block trades and in the open market.
Sanofi CEO Paul Hudson stated: “We achieved double-digit sales growth in 2024 while pursuing the transformation of the company. Innovation was a key driver of our growth as launches already contributed 11% of sales, with Beyfortus becoming a blockbuster in its first full year of sales.
“As we enter 2025, we expect continued, solid growth in sales and a strong rebound in earnings. We are also confident in the mid to long-term growth prospects of Sanofi, supported by ongoing launches, Dupixent (currently expected to reach sales of around €22bn in 2030, in line with the current ambition), and expected future launches from our pipeline.”
In November 2024, the European Medicines Agency Committee for Medicinal Products for Human Use recommended the approval of Sanofi’s Sarclisa with Velcade, plus Revlimid, plus dexamethasone (VRd) for treating newly diagnosed multiple myeloma (MM).
